source
- Ionis secures FDA approval for zilganersen, a first treatment for Alexander diseaseIonis Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its antisense drug zilganersen for the treatment of Alexander disease, an ultra‑rare neurodegenerative disord…
- Novartis' Lp(a) drug pelacarsen fails to cut heart attack or stroke risk in phase 3 trialNovartis, in partnership with Ionis, completed the phase 3 Lp(a)Horizon trial of pelacarsen, an antisense oligonucleotide designed to lower lipoprotein(a) levels. The study enrolled more than 8,30…